Skip to main content
Profound Medical Corp. logo

Profound Medical Corp. — Investor Relations & Filings

Ticker · PROF TSX Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2022-05-09 Regulatory Filings
Country CA Canada
Listing TSX PROF

About Profound Medical Corp.

https://profoundmedical.com/

Profound Medical Corp. is a commercial-stage medical technology company specializing in incision-free ablative therapies. Its core product is TULSA-PRO®, a therapeutic platform designed for the treatment of localized prostate cancer, radiorecurrent prostate cancer, and benign prostatic hyperplasia (BPH). TULSA-PRO utilizes a robotically controlled, transurethral ultrasound ablation procedure guided by real-time Magnetic Resonance (MR) imaging. This system employs closed-loop temperature feedback to ensure precise and customizable tissue ablation, prioritizing patient safety and minimizing complications. The technology merges MR imaging, thermal ultrasound, and robotics to offer a durable and accurate treatment delivery method.

Recent filings

Filing Released Lang Actions
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a Qualification Certificate addressed to multiple Canadian securities commissions. It is a certification by the CEO confirming compliance with specific regulatory instruments (NI 44-101 and NI 44-102) related to short form prospectus distributions and shelf distributions. The document is short (1354 characters) and primarily serves as an officer certification rather than containing financial data or a report. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS).
2022-05-09 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification form (Form 52-109F2) signed by the CEO certifying the review and fairness of the interim financial report and interim MD&A for the period ended March 31, 2022. It focuses on the officer's attestation regarding disclosure controls and internal controls over financial reporting. There are no actual financial statements or substantive financial data presented in this document; it is a certification related to interim filings. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS), not as the interim report itself (IR). The document length is about 5180 characters, which is consistent with a certification letter rather than a full interim report.
2022-05-09 English
Interim MD&A - English.pdf
Regulatory Filings
2022-05-09 English
News release - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a detailed financial report for the first quarter ended March 31, 2022, including comprehensive financial statements such as balance sheets, statements of loss and comprehensive loss, and cash flows. It contains actual financial data, analysis of revenue, expenses, net loss, and liquidity. The presence of detailed quarterly financial results and discussion of business highlights aligns with an Interim / Quarterly Report. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement or press release. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2022
2022-05-09 English
Certificate re dissemination to shareholders.pdf
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a letter from TSX Trust Company confirming the mailing of proxy-related materials including a proxy with request for financial statements, voting instruction forms, notice of meeting combined with information circular, financial statements and MD&A, and proxy return envelope. The document itself is not the proxy materials or the financial statements but an announcement that these materials have been sent to shareholders. The document length is short (1268 characters) and it states that the proxy materials and financial statements are being mailed, indicating it is an announcement rather than the actual report or proxy statement. Therefore, this fits the category of Proxy Solicitation & Information Statement (PSI), as it relates to proxy materials and shareholder voting information.
2022-04-27 English
Notice of meeting - English.pdf
AGM Information Classification · 95% confidence The document is a Notice of Annual and Special Meeting of Shareholders for Profound Medical Corp. It includes details about the meeting date, location, agenda items such as receiving audited financial statements, electing directors, approving share option plans, and appointing auditors. It also provides instructions for shareholders on how to attend or vote. The document is a formal announcement inviting shareholders to the meeting and does not contain the actual financial statements or detailed reports. The length is 3875 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting, including notices of such meetings.
2022-04-26 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.